Xilio Therapeutics Secures $35.8M from Warrant Exercises, Extends Cash Runway into Q2 2027

summarizeSummary

Xilio Therapeutics announced the successful exercise of Series B warrants, generating $35.8 million in gross proceeds and extending its cash runway into the second quarter of 2027.

check_boxKey Events

• Series B Warrants Exercised

  48,207,815 Series B warrants were exercised by December 31, 2025, generating $35.8 million in total gross proceeds for the company.

• Cash Runway Extended

  The company anticipates its existing cash and the proceeds from the Series B warrant exercises will fund operations into the second quarter of 2027.

• Future Capital Potential

  48,207,815 Series C warrants remain outstanding, with an exercise price of $0.75 per warrant, potentially generating up to an additional $36.2 million by the end of 2026.

• Shares Outstanding Update

  As of January 2, 2026, there were 67,540,930 shares of common stock issued and outstanding.

auto_awesomeAnalysis

This 8-K filing details a critical capital infusion for Xilio Therapeutics, which is vital for its operations as a life sciences company. The successful exercise of Series B warrants, generating $35.8 million in gross proceeds, provides substantial funding. This capital, combined with existing resources, is projected to fund operations into the second quarter of 2027, significantly reducing near-term liquidity concerns and providing a longer runway for its clinical programs. Additionally, the company highlights the potential for another $36.2 million from outstanding Series C warrants, further bolstering its financial outlook if exercised, though their exercise price of $0.75 is slightly above the current stock price of $0.6996.